Clin Infect Dis, Vol. 63, suppl 3, 1 November 2016
All articles open access at:
Although the WHO-recommended treatment regimen for children with drug-susceptible tuberculosis is generally well tolerated and leads to good treatment outcomes, 6 months of daily treatment can be challenging for children and families. For multidrug-resistant tuberculosis treatment regimens are long (often for >18 months) and are associated with significant toxicity. There is, therefore, a pressing case for new shorter, well-tolerated regimens that can treat both drug-susceptible and multidrug-resistant organisms. The series of articles in this supplement to Clinical Infectious Diseases very persuasively provides a proof-of-concept framework for how we might identify optimal regimens for children, better predict desired drug exposures, and determine the required dosing needed to optimize mycobacterial killing in children, while limiting toxicity.